Finoriq research workspace
GILEAD SCIENCES, INC. (GILD) SEC Filings & Filing Highlights
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes. Review GILD SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Company
- GILEAD SCIENCES, INC. (GILD)
- Ticker
- GILD
- Market Cap
- $165.7B
- Latest Price
- $133.49
- Industry
- Biotech & Pharma
GILEAD SCIENCES, INC. (GILD) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for GILEAD SCIENCES, INC. (GILD).
| Event | Form | Date |
|---|---|---|
| Other InformationOn May 14, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BofA Securit... | 8-K8.01 | 2026-05-20 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-05-20 |
| Supplemental IndentureOn May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo B... | 8-K1.01 | 2026-05-20 |
| GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTSGILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS | 8-K2.02 | 2026-05-07 |
| Broker Non-VotesThe 2026 annual meeting of stockholders (the “Annual Meeting”) of Gilead Sciences, Inc. (the “Company”) was held on April 30, 2026. Of the... | 8-K5.07 | 2026-05-04 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.